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Sir,
We have read with great interest the article of Kunitoh et al,
2009 published recently on this Journal, about the use of
intrapericardial Bleomycin in malignant pericardial effusion
(MPE) with lung cancer. We appreciate the effort of trying a
prospective, randomised study in this field, but we do not
agree with the rationale and the method of the study.
First of all, the title is misleading, as the Authors also include
cytologically negative effusions among the ‘malignant effusions’,
without any mention about other means to confirm their
malignant nature. At least 30% of pericardial effusions in lung
cancer patients are not due to metastases, and these cases should
be examined separately (Wang et al, 2000; Porte et al, 1999).
Actually, when the Authors did so in the subgroup analysis, the
difference between the two groups of treatment is evident (even
without a statistically significant difference). A title as: ‘Pericardial
effusion in lung cancer patients’ should be more appropriate.
Second, in the introduction, the Authors assume that the
therapy of malignant pericardial effusion is, by definition, peri-
cardial sclerosis, and include the use of various chemotherapeutic
agents such as ‘sclerosing’. Actually, Bleomycin has both anti-
neoplastic and sclerosing (with a mechanism analogue to the tetra-
cyclines) properties, whereas platinum, thiotepa and vinblastine
are actually ‘pure’ antineoplastic drugs. In fact, the goal of the
use of these agents is not to simply prevent mechanically the
accumulation of the pericardial fluid, but try to cure the pericardial
metastases. And this leads to the third, and more important point.
Malignant pericardial effusion is a metastatic localisation,
and, in our opinion, the goal of treatment should be to try to
cure it with antineoplastic agents rather than simply prevent their
secondary effects. Echocardiographic evaluation in many lung
cancer patients detects discrete pericardial implantations or
infiltrations, and in certain patients, diffuses neoplastic deposits.
Thus, local chemotherapy has the rationale to control not only the
pericardial fluid re-accumulation but the neoplastic process
as well. The injection of a chemotherapeutic agent in a limited
space, such as the pericardium, with heart’s movement allowing
the diffusion of the agent to the whole surface, and the slow
re-absorption through the lymphatic vessels (the main diffusion
way of metastases to the pericardium in lung and other cancers),
has several advantages: high intrapericardial concentration of
chemotherapy (CT) for several days, low blood concentration
(and few systemic side effects) and beneficial effects on the
lymphatic system obstruction (Figoli et al, 1987; Reynen et al,
2004; Tomkowski et al, 2004). On the contrary, the exaggerated
sclerosing process after intrapericardial instillation is the main
problem of sclerosing agents, such as bleomycin. The risk of
sclerosing therapy is in fact not only the evolution to constrictive
pericarditis (as already reminded by the Authors), but also to
effusive-constrictive pericarditis (where even small amount of
fluid leads to tamponade because of the reduced compliance of
the thickened pericardium), with consequently problems in
attempting a second drainage in case of haemodynamic impair-
ment if the effusion is loculated. In the report by Kunitoh et al,
among 79 patients, two cases of constrictive pericarditis and two
deaths of massive bleeding ‘during attempt of re-drainage
ypossibly due to crack formation in the ventricular wall upon
dissection of the adherent pericardium’.
We and others have reported the low complication rate and
the effectiveness of local chemotherapy (Lestuzzi et al, 2000;
Maisch et al, 2002; Martinoni et al, 2004; Tomkowski et al, 2004;
Bischiniotis et al, 2005). In our personal experience of 139 cases
of MPE due to various neoplasms (88 lung cancer) and treated
with local chemotherapy (platinum in most cases, given either as
single 50mg in 50ml of saline in single bolus or as 10mg in 20ml
of saline over 3–5 running days), we had no major complications
except for: one case of renal failure (treated with fluid and
furosemide), one severe chest pain with electrocardiogram
abnormalities (but no troponine increase), one atrial fibrillation
requiring DC shock for cardioversion and two late constrictive
pericarditis after local CT with platinum. A minority of patients
complained of pain or nausea. We had no problems in any of the
eight patients who underwent a second pericardiocentesis. In
addition, in one of our Institutions (Theagenion Cancer Hospital)
15 lung cancer patients underwent serial cytological examination
of the pericardial fluid that showed a remarkable neoplastic
burden reduction after the third dose of cisplatin. This acute
response of local chemotherapy may predict its long-term
favourable effects.
About the outcome, our experience is encouraging. In all
tumours, the mean effusion-free period of the patients treated
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www.bjcancer.comwith local chemotherapy was 372 days, median 223; at 1, 2, 6 and
12 months, 58, 52, 33 and 16%, respectively, were completely
effusion-free. In the subgroup of lung cancer MPE, the mean
effusion-free period was 271 days (median 215) and the percentage
of completely effusion-free at 1, 2, 6 and 12 months was 65, 57, 35
and 18%, respectively; also including the patients who had
persistent mild effusion (without haemodynamic impairment).
The success rate in this subgroup raises to 86, 70, 40 and 19%,
respectively. Our results are then slightly better, on the long-term
period, when compared with those of Kunitoh (who reports an
effusion-free survival of 65, 46, 24 and 10% at 1,2,6 and 12 months,
respectively), with fewer complications.
In conclusion, we feel that sclerosing therapy (with any agent)
should not be considered as the first choice treatment for MPE
anymore. The use of local CT agent is safer, more rationale
and more effective. Coping with lung cancer, platinum is the first-
choice drug for systemic therapy (and, logically, for local therapy
as well) (D’Addario and Felip, 2008).
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